An IOM committee focused on biomarkers for molecularly targeted therapies has issued recommendations about regulatory, reimbursement, and clinical practice issues, in order to guide precision medicine in advancing the care of patients with cancer and other diseases.
No takes yet. Share an insight, caveat, or question.
Lyman et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: